Sisram Medical Ltd (Sisram) reported a repurchase of 50,000 ordinary shares on 28 October 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The transaction was executed on-market at prices ranging from HKD 1.835 to HKD 1.89 per share, representing a volume-weighted average cost of HKD 1.8523. Total consideration amounted to HKD 0.09 million.

Following the buyback, Sisram’s issued share capital (excluding treasury shares) fell by 0.011 % to 467.59 million shares. Treasury shares rose to 748,400, while the company’s total issued share count remained unchanged at 468.34 million shares.

The purchase was made under the general mandate approved on 24 June 2026, which authorises the company to repurchase up to 46.83 million shares. Cumulative repurchases under this mandate now stand at 748,400 shares, equivalent to 0.16 % of the issued share base at the mandate date.

In line with Hong Kong listing rules, Sisram is subject to a moratorium on issuing new shares or disposing of treasury shares until 27 November 2026. The board confirmed that the repurchase complied with all relevant regulatory requirements and that all requisite payments and filings have been completed.